sur Jaguar Health, Inc. (NASDAQ:JAGX)
Jaguar Health Regains Nasdaq Compliance
Jaguar Health, Inc. (NASDAQ:JAGX) has announced that it is back in compliance with Nasdaq's Bid Price Rule as of May 26, 2026. The company's securities continue to be listed and traded on Nasdaq, marking an important milestone. This achievement follows a period of strategic efforts to adhere to Nasdaq listing criteria, which Jaguar views as a significant asset.
Lisa Conte, Jaguar's president and CEO, highlighted the company's remarkable financial progress. Jaguar reported an 816% increase in net revenue in Q1 2026 compared to Q1 2025. This leap in revenue is attributed to the out-license agreement with Future Pak. Jaguar remains focused on its crofelemer development program, with plans to file a New Drug Application by mid-2027 and seeks a partner for further development and commercialization.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Jaguar Health, Inc.